Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980576 | 0.87 | LMNA (0.64) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL30980762 | 0.82 | LMNA (0.58) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL30980695 | 0.80 | LMNA (0.60) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL30980778 | 0.80 | HTT (0.44) | LMNASMN1; SMN2HTTTGM2ANPEP | |
| SCHEMBL31078952 | 0.77 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2HTTGHSRL3MBTL1 | |
| SCHEMBL3225482 | 0.77 | SMN1; SMN2 (0.50) | LMNASMN1; SMN2HTTHRH4 | |
| SCHEMBL7466451 | 0.73 | HTT (0.61) | LMNASMN1; SMN2HTTTGM2ANPEP | |
| SCHEMBL20393801 | 0.71 | TDP1 (0.38) | L3MBTL1 | |
| SCHEMBL30823376 | 0.71 | SMN1; SMN2 (0.97) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL7372302 | 0.69 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024155747-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |